Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma

Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) ‎ for the treatment of patients with renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news